Concepedia

Author

Shukui Qin

81th Hospital of PLAORCID

Also Known As

Arndt Vogel, Hirokazu Shoji, Qin, S., Qin, Shantian, S Qin, S. K. Qin, S. Qin, S.K. Qin, SHU-KUI QIN, SHUKUI QIN

573

Publications

50.9K

Citations

76

H-Index

101

Concepts

All Affiliations

81th Hospital of PLASun Yat-sen UniversityPeking UniversityPeking University Cancer HospitalHarbin Medical University
SQ

About

Shukui Qin is an author at 81th Hospital of PLA specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

45

111

26.6K

2

Health Sciences

25

40

18.7K

3

Cell Biology

8

8

296

4

Gastroenterology

8

8

362

5

Diagnostic Sciences

1

1

12

Shukui Qin

×

206

Publications

46.9K

Citations

72

H-Index

YearCitations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda,

New England Journal of Medicine

2020

6.8K

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen,

The Lancet Oncology

2008

5.8K

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin,

The Lancet

2018

5.3K

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle,

The Lancet

2016

3.6K

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda,

Journal of Hepatology

2021

1.5K

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo,

NEJM Evidence

2022

1.3K

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima, Manish A. Shah, Kei Muro,

Journal of Clinical Oncology

2020

1.1K

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu,

Journal of Clinical Oncology

2016

976

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu,

The Lancet Oncology

2015

791

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park,

Journal of Clinical Oncology

2013

765

Page 1